MIRENA 20mcg/24h Price

Overview

Welcome to Dwaey, specifically on MIRENA 20mcg/24h Implant system/Intrauterine page.
This medicine contains an important and useful components, as it consists of Levonorgestrel.
MIRENA 20mcg/24h is available in the market in concentration 52mg/System and in the form of Implant system/Intrauterine.

BAYER OY is the producer of MIRENA 20mcg/24h and it is imported from FINLAND, The most popular alternatives of MIRENA 20mcg/24h are listed downward .

Mode Of Action

Levonorgestrel, a nortestosterone derivative, is an active isomer of norgestrel. It is a potent inhibitor of ovulation and has androgenic activity.

Indication

• Contraception
• Emergency contraception
• Menopausal hormone replacement therapy
• Menorrhagia

Precaution

Sex-steroid dependent cancer, past ectopic pregnancy, malabsorption syndromes, functional ovarian cysts, active liver disease, recurrent cholestatic jaundice, history of jaundice in pregnancy, CV or renal impairment, DM, asthma, epilepsy, migraine, conditions aggravated by fluid retention, depression and thromboembolism (high doses); lactation.

Side Effects

• >10% Headache (12%)
• Acne (15%)
• Ovarian cysts (13%)
• Enlarged follicles (12%)
• Amenorrhea (1-12%)
• Abdominal pain (12%)
• Uterine/vaginal bleeding alterations (52%)
• Intermenstrual bleeding/spotting (23%)
• Vulvovaginitis (20%)
• Ectopic pregnancy (?50%) 1-10% Depression (4%)
• Migraine (2%)
• Alopecia (1%)
• Dysmenorrhea (9%)
• Menorrhagia (6%)
• Breast tenderness (3-9%)
• Pelvic pain (6%)
• Leukorrhea (5%)
• Vaginal discharge (4%)
• Pelvic infection (1%) <1% Angioedema
• Cervical perforation
• Failed insertion
• Sepsis
• Uterine bleeding
• Device breakage Potentially Fatal: Thrombocytopenia
• stroke.

Contra indication

Pregnancy, undiagnosed vaginal bleeding, severe arterial disease; liver adenoma, porphyria; after recent evacuation of hydatidiform mole; history of breast cancer; hepatic impairment.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.